<table border="1" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="148.5pt"></col>
<col width="121.5pt"></col>
<col width="170.6pt"></col>
<thead>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Concomitant Drug Name</content>
</paragraph>
</td>
<td stylecode="    Lrule     ">
<paragraph>
<content stylecode="bold">Effect of Carbamazepine on Other
   Drugs</content>
</paragraph>
</td>
<td stylecode="    Lrule     ">
<paragraph>
<content stylecode="bold">Clinical Recommendation</content>
</paragraph>
</td>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Boceprevir</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in boceprevir levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Coadministration
  of carbamazepine with boceprevir is contraindicated</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Acetaminophen,
  albendazole, alprazolam, aprepitant, buprenorphone, bupropion, citalopram,
  clonazepam, clozapine, corticosteroids (e.g., prednisolone, dexamethasone),
  cyclosporine, dicumarol, dihydropyridine calcium channel blockers (e.g.,
  felodipine), doxycycline, ethosuximide, everolimus, haloperidol, imatinib,
  itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, mianserin,
  midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine,
  paliperidone, phensuximide, phenytoin, praziquantel, protease inhibitors,
  risperidone, sertraline, sirolimus, tadalafil, theophylline, tiagabine, topiramate,
  tramadol, trazodone, tricyclic antidepressants (e.g., imipramine,
  amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in concomitant drug levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor
  the concentration and consider a dosage adjustment of the concomitant drug(s)</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Cyclophosphamide</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Increase
  in cyclo-phosphamide levels (potential for increased toxicity) </paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor
  for signs of increased cyclophosphamide toxicity</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Aripiprazole</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in aripiprazole levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>When
  carbamazepine is added to aripiprazole, the aripiprazole dose should be
  doubled; additional dose increases should be based on clinical evaluation; when
  carbamazepine is withdrawn from the combination therapy, the aripiprazole
  dose should be reduced</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Tacrolimus</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in tacrolimus levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor
  tacrolimus blood concentrations and make appropriate dosage adjustments</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Temsirolimus</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in temsirolimus levels </paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The
  use of concomitant strong CYP3A4 inducers such as carbamazepine should be
  avoided with temsirolimus; if carbamazepine must be coadministered with
  temsirolimus, consider adjusting the dosage of temsirolimus</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Lapatinib</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in lapatinib levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The
  use of carbamazepine with lapatinib should generally be avoided; dosage
  adjustment should be considered if lapatinib is coadministered with
  carbamazepine; if carbamazepine is started in a patient already taking
  lapatinib, the dose of lapatinib should be gradually titrated up; if
  carbamazepine is discontinued, the lapatinib dose should be reduced</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Nefazodone</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in nefazodone levels </paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Coadministration
  of carbamazepine with nefazodone is contraindicated</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Valproate</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Decrease
  in valproate levels</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor
  valproate concentrations when carbamazepine is introduced or withdrawn in
  patients using valproic acid</paragraph>
</td>
</tr>
</tbody>
</table>